inhibitors, which activate endothelial nitric oxide synthase (NOS). NOS-related blood flow increases within one month in hypercholesterolemic patients treated with a low dose of atorvastatin (10 mg daily), 1 and within 24 hours in healthy subjects treated with high dose atorvastatin (80 mg daily). 2 Statins have shown promise for SCA in the sickle cell mouse, 3 in human neutrophils ex vivo, 4 and in children with sickle cell disease. 5 SCA subjects were selected from the NIH sickle cell cohort to enrich for vascular dysfunction evidenced by any of the following three characteristics: a higher than median plasma level of soluble vascular cell adhesion molecule (sVCAM-1)(>795 ng/mL; 14 subjects), 6 or a tricuspid regurgitant velocity (TRV) ≥2.5 m/s by Doppler echocardiography (11 subjects; 2 of the high sVCAM-1 group also had TRV ≥2.5 m/s). 7 Other inclusion and exclusion criteria were similar to a previous study. 8 African-
American adults without sickle cell trait served as controls only for characterization of baseline blood flow, and did not participate in the treatment study. All subjects signed informed consent forms for a research protocol approved by the institutional review board of the National Heart, Lung and Blood Institute (ClinicalTrials.gov identifier NCT00072826). Data were analyzed with the Prism 4.0 statistical package (GraphPad Software, La Jolla, CA, USA), with Spearman correlations, paired t-test, and one-way or two-way analysis of variance of the mean (ANOVA) with repeated measures as appropriate, statistical significance assumed at p<0.05.
Twenty-five subjects with SCA (11 male, 14 female; median age 36 years) and 10 healthy subjects (6 male, 4 female; median age 37 years) were enrolled. Detailed laboratory characteristics are provided in Supplemental Table 1 . The subjects with SCA demonstrated baseline forearm blood flow (FBF) characteristics that confirmed the previously reported defect in nitric oxide-dependent blood flow (Supplemental Figure   1 ). 8, 9 Our recruitment strategy successfully enriched for SCA subjects with vascular dysfunction. All enrolled SCA subjects had a blunted vasodilatory response to a nitric oxide (NO) donor compared to the healthy subjects that recapitulates that previously reported in SCA mice, 10, 11 and in about three-quarters of sickle cell anemia patients. 8, 9, 12 Atorvastatin significantly reduced serum cholesterol, low density lipoprotein cholesterol (LDL-C), and triglyceride levels in a dose dependent manner ( Figure 1 ).
These changes were equivalent in both male and female subgroups. There was no change in serum high density lipoprotein cholesterol (HDL-C). These observations indicate successful inhibition of HMG CoA reductase, the intended target of statin drugs, and provide functional evidence of subjects' adherence to study treatment. Despite the statistically significant favorable effect of atorvastatin upon lipid profiles, vasodilatory responses to an NO donor and NOS inhibitor were not affected (Supplemental Figure   2 ). Because change in NOS inhibitor response was the pre-specified primary outcome variable, this is therefore a negative study. However, some of the important prespecified secondary outcome variables showed statistically significant changes in 
6
This last finding raises the question whether higher doses of atorvastatin or earlier intervention for longer duration should be considered for future investigation to delay vascular dysfunction in SCA patients.
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SUPPLEMENTARY METHODS AND RESULTS
Venous occlusion plethysmography
Forearm blood flow (FBF) measurements were performed by means of strain gauge venousocclusion plethysmography. Briefly, a mercury-filled Silastic strain gauge was placed around the widest portion of the forearm, and connected to a plethysmograph calibrated to measure the percent change in volume. The plethysmograph is connected to a computer for FBF measurements following inflation of a wrist cuff to suprasystolic pressure to exclude the hand circulation. A blood pressure cuff on the upper arm was inflated to 50 mmHg for 7 seconds with a rapid cuff inflator in order to occlude venous outflow, but not arterial inflow, into the forearm. This causes indiscernible distention of the forearm at a rate proportionate to arterial inflow. A series of 7 sequential blood flow measurements are averaged for each blood flow value. Blood pressure was recorded directly from the intra-arterial catheter immediately after each series of flow measurements.
Subjects with sickle cell disease underwent catheterization of the brachial artery with baseline blood sampling. FBF was measured following 20 minutes of normal saline infused at 1 mL/min into the brachial artery. The endothelium-independent vasodilator sodium nitroprusside was infused at 0.8, 1.6, and 3.2 µg/min respectively, in order to test the vascular responsiveness to an NO donor. After three minutes of each infusion, forearm flows were measured. After a 20-minute rest period, another baseline measurement was obtained and the endothelium-dependent vasodilator acetylcholine was infused at 7.5, 15, and 30 µg/min respectively, to test for endothelial release of relaxant factors including NO. After three minutes of each infusion, forearm flows were measured. Following a 30-minute rest period, the NOS inhibitor L-NMMA was infused at 4 and 8 µmol/min, to test basal production of NO. After three minutes of each infusion, FBF was measured. At the conclusion of the measurements on L-NMMA at 8 µmol/min, combine infusion of L-NMMA 8 µmol/min with acetylcholine at 30 µg/min for 3 minutes was administered, and then FBF was measured. The extent to which L-NMMA reduced acetylcholine induced vasodilation indicate the degree of agonist-stimulated NOS-dependent FBF. Markers of endothelial and monocyte activation in SCD and controls. Plasma levels were significantly higher than healthy African-American control subjects (n=9) in SCD subjects (n=22) at baseline for (A) soluble vascular cell adhesion molecule-1 (sVCAM-1, p<0.001, unpaired t-test); (Β) monocyte chemokines RANTES (p=0.002, unpaired t-test); and (C) macrophage inflammatory protein 1β (MIP-1β, p<0.001, Mann-Whitney test). Following the four week course of atorvastatin in the SCD subjects, no significant changes were observed in these three variables (p>0.05, Wilcoxon matched-pairs signed rank test or unpaired t-test).
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